#lawsuit

The lawsuit seeks to force prisons to step up to the plate with hep C therapy and follows others filed in numerous states.

Three distributors and a drugmaker may avert the first federal trial over their role in the U.S. opioid crisis.

The suit alleges “cruel and unusual punishment” by state prison officials.

Massive legal payouts are likely coming—but it’s still unclear where they will go.

Abu-Jamal spent years fighting for access to hepatitis C treatment in prison.

This is one of several lawsuits filed by advocates on behalf of inmates with the liver virus in U.S. prisons.

At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.

Plaintiffs in Georgia, Michigan, Kansas and Missouri say new rules will leave less populous areas with fewer organs than urban regions.

The right was secured via a class-action lawsuit settlement.

Three lawsuits allege prison officials denied them treatment for more than a year, despite serious illness.

Nearly 3,800 patients at the New Jersey surgery center may have been exposed, though the risk of infection is low.

The pharmacy chains were added to an existing lawsuit against opioid distributors and manufacturers.

The settlement ensures all affected state prisoners will be treated for the disease.

This is big news in a federal lawsuit brought by three inmates against the state’s department of corrections.

The case alleged that the state’s Medicaid system was setting too many barriers for HCV-positive patients.

Six years after the arrest of medical technician David Kwiatkowski, the legal fight against Exeter Hospital is coming to a close.